On April 20, 2026, the Board of Directors of Sai Parenteral’s Limited convened and approved a significant financial move to bolster its international presence. The Board sanctioned the provision of financial assistance via an unsecured loan to its wholly owned subsidiary, Sai Singapore Pte. Ltd.. This funding is specifically earmarked for downstream investment into Noumed Pharmaceuticals PTY Limited, Australia, which serves as a step-down subsidiary for the company. The meeting, which began at 12:00 Noon and concluded at 02:40 PM, marks a decisive step in the company’s capital allocation strategy for its global operations.

The approved financial assistance is capped at AUD 1.75 million (approximately SGD 1.61 million), which converts to roughly INR 119.14 million. This strategic loan facilitates the “downstream funding” required for Noumed Pharmaceuticals, a key asset in Sai Parenteral’s expansion into regulated markets like Australia. By channeling these funds through its Singaporean arm, the company is effectively strengthening its foothold in the Australian pharmaceutical landscape, leveraging its existing step-down subsidiary structure to enhance its international manufacturing and distribution capabilities.

Sai Parenteral’s Limited is a Hyderabad-based specialty pharmaceutical player that has evolved from a parenteral-focused manufacturer into a diversified formulations platform. The company operates five manufacturing facilities across Telangana and Andhra Pradesh, producing a wide range of dosage forms including injectables, tablets, and capsules across therapeutic areas like cardiovascular and anti-diabetic care. In a major update from 2025, the company filed its Draft Red Herring Prospectus (DRHP) with SEBI on September 30, 2025, to transition into a publicly listed entity. A pivotal milestone in 2025 was the acquisition of a 74.6% controlling stake in Noumed Pharmaceuticals (Australia) in October, which granted the company access to 451 TGA-registered dossiers. Furthermore, in July 2025, the company raised INR 500 million in venture funding to accelerate its R&D and support upcoming product launches.

Regarding its financial trajectory, the company reported a consistent growth pattern in its Fiscal Year 2025 results. Revenue from operations for FY25 reached INR 1,631.1 million, a steady increase from INR 1,537.6 million in FY24. Profit After Tax (PAT) saw a significant surge, rising to INR 144.5 million in FY25 compared to INR 84.15 million in the previous year. The company has attracted attention from high-profile backers, including Nikhil Kamath (Co-Founder of Zerodha) and Mohandas Pai (Former CFO of Infosys). Additionally, prominent institutional investors such as Morgan Stanley Asia and Kotak Lifesciences Fund participated as anchor investors during its 2026 listing process, reflecting strong market confidence in its growth model.